Скачать или смотреть Anthem Biosciences Share Analysis | Strong Q1 Results | Undervalued Biotech Stock | Share News Today

🔥 Anthem Biosciences Q1 FY26 Results are out! Company ne report kiya 60% revenue growth aur 65% profit jump, with industry-leading 38% EBITDA margin. With CRDMO and Specialty Ingredients business model, Anthem is becoming a global partner of choice in pharma and biotech.

🏭 Key Highlights

Revenue from Ops: ₹5,402 Cr (+60% YoY)

PAT: ₹1,358 Cr (+65% YoY), Margin 24%

CRDMO: 84% of revenue, Specialty Ingredients: 16%

Net Cash Position: ₹7,848 Cr, Strong Balance Sheet

Expansion: Unit II & III (Harohalli) operational, Unit IV Greenfield under construction

ROE 21.8%, ROCE 28.2%

📈 Growth Outlook: Global demand for CRDMO services, strong client partnerships, and capital-efficient expansions will drive long-term value.

⚡ Big Question: Is Anthem Biosciences an Undervalued Stock, a potential Future Multibagger, and a long-term Wealth Creator in biotech?

👉 Watch till the end for complete financial analysis, business model, risks, and future outlook.

#FutureMultibagger #WealthCreator #UndervaluedStock #AnthemBiosciences #BiotechStocksIndia #StockMarketIndia #Q1Results